All News

At ESC 2025, the STEER study showed semaglutide reduced risk of heart attack, stroke, or death by 57% vs tirzepatide in adults with obesity and cardiovascular disease, complementing prior trial data.

Your daily dose of the clinical news you may have missed.

The FDA has cleared Eisai and Biogen’s Leqembi Iqlik, the first at-home subcutaneous autoinjector for maintenance therapy in patients with early Alzheimer disease.

Your daily dose of the clinical news you may have missed.

Seniors remain protected along with any adult or child with underlying risk factors for severe disease, but the healthy US population is left with a choice, so far.

Primary care clinicians see a higher share of visits for depression than mental health professionals largely because they know their patients so well, Lovins said.

Based on the FAQ section in the ACC's 2025 Concise Clinical Guidance on vaccination in adults with CVD, this short slideshow also offers recommended answers.

Teva announced approval of the generic formulation of Saxenda, which could help expand access to the extremely popular class of antiobesity medications.

Your daily dose of the clinical news you may have missed.

Teresa Lovins, MD, highlights a study that showed a 14% increase in rates of safety planning within 2 weeks of a negative screening led to a 25% decrease in attempted suicides.